New treatment shows promise against fatal neurological disease: Study
A new treatment shows promise against the deadly neurodegenerative disease ALS, a study based on mice showed Tuesday.
Jan 31, 2024
0
85
A new treatment shows promise against the deadly neurodegenerative disease ALS, a study based on mice showed Tuesday.
Jan 31, 2024
0
85
Radiotherapy, which uses high-energy radiation to kill cancer cells, typically follows a dosing and treatment plan based on clinical research to minimize the impact of the radiation on healthy tissues. However, since the ...
Jan 31, 2023
0
90
In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted ...
Jan 31, 2023
0
73
Molecular damage accumulates and contributes to the development of aging-related frailty and serious diseases. In some people these molecular processes are more intense than in others, a condition commonly referred to as ...
Sep 27, 2022
0
473
The U.S. federal government spent an estimated $1.8 billion in Medicare funds in 2019 on drugs whose clinical benefits have yet to be confirmed by the Food and Drug Administration, a new study led by researchers from the ...
May 24, 2022
0
277
If you're about to run headfirst into something, your reflex might be to tense your neck and stabilize your noggin. But according to new research from Stanford University that may not be the best way to stave off a concussion. ...
Aug 22, 2018
1
44
A marathon runner approaches the finishing line, but suddenly the sweaty athlete collapses to the ground. Everyone probably assumes that this is because he has expended all energy in his muscles. What few people know is that ...
Mar 4, 2013
1
0
New research questions the effectiveness of the U.S. Food and Drug Administration's accelerated drug approval program after finding that many cancer drugs remain unproven five years later.
Apr 8, 2024
0
2
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed ...
Mar 19, 2024
0
3
Over the past decade, regulatory agencies such as the Federal Drug Administration (FDA) in the United States and the and the European Medicines Agency (EMA) in the European Union have put programs in place to get new drugs ...
Mar 13, 2024
0
0